RT Journal Article
SR Electronic
T1 Prolonged Administration of Adjuvant Temozolomide Improves Survival in Adult Patients with Glioblastoma
JF Anticancer Research
JO Anticancer Res
FD International Institute of Anticancer Research
SP 3467
OP 3474
VO 33
IS 8
A1 AMÉLIE DARLIX
A1 CÉDRIC BAUMANN
A1 VÉRONIQUE LORGIS
A1 FRANÇOIS GHIRINGHELLI
A1 MARIE BLONSKI
A1 BRUNO CHAUFFERT
A1 SONIA ZOUAOUI
A1 CATHERINE PINELLI
A1 FABIEN RECH
A1 PATRICK BEAUCHESNE
A1 LUC TAILLANDIER
YR 2013
UL http://ar.iiarjournals.org/content/33/8/3467.abstract
AB Background: Radiotherapy with concomitant and adjuvant temozolomide (six cycles) is the standard treatment after surgery in glioblastoma patients. Few studies have assessed the impact of additional cycles of temozolomide on survival. Patients and Methods: We conducted a bi-centric retrospective study comparing survival and toxicity according to the number of cycles of adjuvant temozolomide. Results: Fifty-eight patients were included. All patients received radiotherapy with concomitant temozolomide. Thirty-eight patients received six cycles, while 20 received nine or more (median=14) cycles. The risk of recurrence was significantly higher in the group receiving six cycles compared to the other group. Prolonged treatment improved progression-free survival (p=0.03) and overall survival (p=0.01) in multivariate analysis without a significant increase in toxicity. Conclusion: Prolonged administration of temozolomide seems to improve progression-free and overall survival, without increased toxicity. Prospective studies in larger populations are needed to better-define the population to whom it can be proposed and its optimal duration.